News
The antibody titers, measured in ELISA units/ml, induced by Cervarix remain 13- and 12-fold higher than natural infection titers at 6.4 years for HPV-16 and -18, respectively, with over 98% of the ...
Intergroup differences (95% CI) in percentages of subjects with antipneumococcal IgG concentrations ≥0.35 μg/mL against PCV vaccine antigens at 7 months of age between subjects who received 3 ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the completion of initial patient screening in the ...
HPV 16 and 18 have been linked to 66% of all cervical cancer diagnoses. HPV 31, 33, 34, 45, 52, and 58 are also associated with cancers. Roughly 90% of genital warts outbreaks are caused by HPV 6 and ...
One of the most effective vaccines available was going to become more accessible—until RFK Jr. dismissed the CDC’s advisory ...
China’s first domestically developed nine-valent human papillomavirus (HPV) vaccine has been approved for marketing by the National Medical Products Administration, breaking the more than decade ...
Abstract and Introduction Abstract Cervarix® and Gardasil® are two prophylactic HPV vaccines designed primarily for cervical cancer prevention. Cervarix is effective against HPV-16, -18, -31, -33 and ...
Hosted on MSN16d
The HPV vaccine can prevent genital cancers, but fewer teens are getting the jab - MSNThe HPV vaccine, delivered in schools, is the frontline defence in shielding the body from HPV infection. HPV causes cervical cancer, genital, anal and oral cancers — as well as genital warts.
A draft agenda for an upcoming meeting of CDC vaccine experts indicated on Wednesday that there would be no discussion about human papillomavirus (HPV) vaccines, a move favorable to Merck (NYSE:MRK), ...
A newly posted agenda for next week’s meeting of the just-appointed group of outside vaccine advisers to the US Centers for Disease Control and Prevention includes a discussion and vote on ...
Papanicolaou (Pap) testing and screening for high-risk strains of HPV, which cause roughly 95% of cervical cancer cases globally, can help identify those at risk of developing the disease and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results